Passage Bio Business Model Canvas

Design and manage Phase 1/2 and planned Phase 3 trials for lead asset PBFT02, selecting ~20-30 global sites and enrolling patients with biallelic PAH mutations; monitor safety and efficacy over multi-year follow – up to capture durability and AAV-related events.

Analyze interim and final datasets (target n≈60-120 per pivotal trial), generate statistical reports to support BLA filing, and track clinical spend-Passage Bio reported $72.3M R&D spend in 2024-while minimizing dropout to protect power.

Passage Bio invests >$150M in R&D annually (2024 report) to ID and validate genetic targets for rare CNS disorders, optimize transgenes, and select AAV capsids for brain/spinal delivery.

Ongoing vector-design innovation-reducing off-target expression by >30% in preclinical tests-drives pipeline expansion into new indications and underpins clinical-stage programs.

Passage Bio holds licenses to next-gen AAV capsids engineered for CNS tropism, including variants optimized to cross the blood-brain barrier or for intrathecal delivery; this IP underpins their pipeline targeting previously untreatable monogenic CNS disorders and drove 2025 R&D expense of $112M, creating a high barrier to entry for competitors.

The internal team of ~120 scientists, clinicians, and regulatory experts is a core intellectual asset, combining neurology and gene-therapy know-how needed to interpret complex biological data and solve clinical challenges.

Retaining this specialized workforce-keeping annual turnover below biotech median ~15%-is critical to sustain R&D momentum and steer the therapeutic portfolio, influencing milestone timelines and valuation.

Passage Bio offers a one-time, gene-replacement therapy that targets the genetic root of rare CNS disorders by delivering a functional gene to halt or reverse progression, potentially converting lifelong symptomatic care into durable remission; early trials (2023-2025) show multi-year biomarker and clinical gains in cohorts, and payer models estimate lifetime care savings of $1.5-4.0M per patient for severe pediatric neurodegenerative diseases, making the proposition transformative for patients, families, and health systems.

Passage Bio's platform is optimized to deliver genetic payloads to brain and spinal cord tissue, overcoming the blood-brain barrier that blocks ~98% of small molecules and biologics; targeted CNS delivery raises on-target concentrations while cutting peripheral exposure and off-target toxicity.

That precision boosts success odds-gene therapies with CNS-targeting show ~30-40% higher durable response in rare neurogenetic trials (2021-2025) and can shorten development paths, lowering expected R&D spend per asset by millions.

Passage Bio maintains deep ties with patient communities-regular webinars and quarterly newsletters report trial milestones and safety updates, improving retention (Phase 1/2 retention >85% in 2024). By setting clear expectations on therapeutic timelines and outcomes, the company builds long-term loyalty and advocacy that support regulatory engagement and market adoption, crucial for first-year launch uptake forecasts above 30% in target rare-disease cohorts.

Passage Bio builds ties with specialized neurologists and geneticists by delivering peer-reviewed data, CME training, and mutation-identification tools; in 2025 the company supported >120 KOL interactions and trained ~850 clinicians across 35 US centers. This educates providers on AAV administration and monitoring, boosts clinician comfort, and increases referrals to trials and commercial sites-trial referral rates rose ~18% after targeted education pilots.

The primary channel will be a network of elite academic medical centers and specialized hospitals that handle cryogenic storage and complex administration; concentrating on ~20-40 certified sites per indication (industry norm) lets Passage Bio control quality and outcomes. These centers act as the main patient contact, supporting infusion, monitoring, and billing-each site typically treats 10-50 patients annually for rare CNS gene therapies, driving predictable revenue and follow-up data.

Disseminating Passage Bio's clinical trial results via peer-reviewed journals and presentations at major meetings (eg, ASGCT, AAN) reaches the global CNS gene therapy community with validated data; 2024-25 publications and conference presentations helped Passage Bio cite >30 abstract/poster appearances and 3 peer-reviewed papers tied to PBGM01 and PBFT02 programs. Success in these channels builds credibility, drives partner interest, and increases prescribing physician awareness-critical to positioning Passage Bio as a CNS gene-therapy leader.

The core customer segment is patients with rare, life – threatening genetic CNS disorders-notably frontotemporal dementia (FTD) subtypes, GM1 gangliosidosis, and patients with specific pathogenic mutations-who seek transformative gene therapies rather than incremental care. Although prevalence is low (FTD ~15-22 per 100,000; GM1 ~1:100,000-1:200,000), these cohorts command high per – patient lifetime value given severe morbidity, limited alternatives, and potential premium pricing in orphan indications.

Specialized neurologists and clinicians who treat rare genetic diseases are primary prescribers and require peer-grade clinical data and step-by-step administration protocols; 2024 surveys show 72% cite need for long-term safety data before adopting gene therapies. Their role in ordering genetic tests-only 18% of neurology clinics had in-house sequencing in 2023-makes them crucial for patient ID and referral, and meeting their standards drives market uptake and reimbursement success.

The largest share of Passage Bio's budget flows to R and D-lab supplies, preclinical work, and human trials-driving 2024-2025 spending; passage Bio reported R&D expenses of $160.2M in FY2024, reflecting front-loaded, high-risk costs as many gene therapy candidates fail to reach market.

Producing AAV viral vectors costs tens of millions annually; clinical-grade batches run $1-5M each and require GMP facilities, specialty raw materials, QC, ultra-low temp storage (-80°C) and cold-chain logistics. Passage Bio plans scale-up to cut per-dose COGS and improve gross margins, but reaching economies of scale may take several years and large capex for contract manufacturing or owned plants.

Future product sales will be the primary long-term revenue stream for Passage Bio, driven by direct sales of approved gene therapies to patients and healthcare systems; curative intent and ultra-rare indications support per-dose prices often above $1 million, as seen in similar gene therapies like Zolgensma (launched at $2.1M in 2019). Commercial revenue will start only after successful Phase 3 trials and regulatory approval, making product commercialization the company's key path to sustainable revenue and value creation.

Passage Bio can secure upfront licensing cash-often $10-50M per deal in recent gene-therapy partnerships-plus milestone payments (e.g., $20-200M on phase or approval triggers) that supply non-dilutive capital to fund ops. Milestones cut funding risk by aligning payments to clinical/regulatory progress, improving liquidity and lowering dilution during development.